STOCK TITAN
  1. Home
  2. News
  3. QSAM

QSAM BIOSCIENCES INC - $QSAM STOCK NEWS

Welcome to our dedicated page for QSAM BIOSCIENCES news (Ticker: $QSAM), a resource for investors and traders seeking the latest updates and insights on QSAM BIOSCIENCES stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect QSAM BIOSCIENCES's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of QSAM BIOSCIENCES's position in the market.

News
QSAM ANNOUNCES REVERSE STOCK SPLIT RATIO AHEAD OF MERGER
Rhea-AI Summary
QSAM Biosciences, Inc. announces a 1-for-2,000 reverse stock split ratio ahead of the merger with Telix Pharmaceuticals The merger is expected to close in early May, subject to conditions. Shareholders will receive cash or Telix Ordinary Shares and contingent value rights (CVRs) for fractional shares.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
stock split acquisition
-
News
QSAM Biosciences Signs Definitive Agreement to be Acquired by Telix Pharmaceuticals
Rhea-AI Summary
QSAM Biosciences Inc. has signed a definitive Agreement and Plan of Merger with Telix Pharmaceuticals Limited, providing for the acquisition of the Company by Telix. The Agreement includes a consideration of $33.1 million in Telix ordinary shares or cash, along with contingent value rights to receive future payments of up to $90 million upon the achievement of four clinical and commercial milestones within ten years of closing. QSAM stockholders will also receive one CVR for each QSAM common share held prior to the reverse split. The merger is subject to various conditions, including the filing of a definitive information statement pursuant to Regulation 14C of the Securities Exchange Act of 1934. Dr. C. Richard Piazza, QSAM’s Executive Chairman and co-Founder, expressed optimism about the merger, emphasizing the potential benefits for shareholders. Dr. Christian Behrenbruch, Managing Director and Group CEO of Telix, highlighted the acquisition's potential to enhance Telix’s therapeutic pipeline and innovation position in radiopharmaceuticals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
31.57%
Tags
acquisition
-
News
QSAM Biosciences Signs Term Sheet to be Acquired by Telix Pharmaceuticals; Receives $2 Million Pre-Closing Collaboration and Option Fee
Rhea-AI Summary
QSAM Biosciences Inc. (OTCQB: QSAM) signs non-binding term sheet with Telix Pharmaceuticals (US) Inc., a subsidiary of Telix Pharmaceuticals Limited (ASX: TLX), for the acquisition of the Company. Telix to pay US$2 million Collaboration Fee and potential total of US$123.1 million in stock and milestone payments. Acquisition expected to accelerate development of CycloSam® and leverage Telix's distribution expertise.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
34.77%
Tags
acquisition
News
QSAM Biosciences Provides Update to Shareholders on Phase 1 Progress and Preliminary Clinical Data
Rhea-AI Summary
QSAM Biosciences Inc. provides an update on the progress and preliminary data from its Phase 1 trial studying the safety and early signs of efficacy of CycloSam® in patients with bone cancer. The trial showed no serious adverse events and maintained normal blood cell counts. Preliminary findings indicate a decrease in metabolic activity of cancer cells and reduction in tumor size. Patients also experienced significant pain relief and improved mobility. The company plans to complete Phase 1 in Q1 2024 and seeks capital through an underwritten offering and NASDAQ listing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.59%
Tags
clinical trial
-
News
QSAM Biosciences Adds the Nuclear Reactor at the University of Texas at Austin to its Radioisotope Production Supply Chain for its Bone Cancer Treatment Drug Candidate, CycloSam®
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.06%
Tags
none
-
News
QSAM Biosciences Expands its Study of CycloSam® in the Treatment of Bone Cancer; Opens Patient Enrollment at Key Chicago Center, Insight Hospital and Medical Center
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.96%
Tags
none
News
QSAM Biosciences and RLS Announce Clinical and Commercial Supply Agreement for Promising Clinical-Stage Metastatic and Primary Bone Cancer Treatment, CycloSam®
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2%
Tags
none
-
News
QSAM Biosciences Receives Second Key Patent in Europe for its Clinical Stage Radiopharmaceutical Drug Candidate, CycloSam®
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
22.61%
Tags
none
-
News
QSAM Biosciences Opens Enrollment of the Second Cohort of Patients in its Phase 1 Study of CycloSam® Targeting Metastatic Bone Cancer
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.97%
Tags
clinical trial
News
QSAM Biosciences to Provide Updates on its Clinical Trial at the Emerging Growth Conference on Wednesday, March 22, 2023
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.59%
Tags
clinical trial
Stock QSAM logo
QSAM BIOSCIENCES INC

OTC:QSAM

QSAM Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

QSAM Stock Data

32.90M
2.07M
52.36%
Polish and Other Sanitation Good Manufacturing
Manufacturing
Link
United States of America
Palm Beach

About QSAM

q2earth inc, formerly q2power technologies, inc., is engaged in manufacturing of compost and engineered soils from recycled waste for the agriculture, horticulture, construction and infrastructure sectors. the company, through acquisitions, is focused on creating and marketing beneficial reuse end products. the company provides green waste hauling under long term contracts, and then manufactures and sells high quality soils to customers that include scotts miracle-gro, old castle and large scale agricultural firms. the company, through its subsidiary george b. wittmer associates inc. (gbwa), is a residual waste management and compost manufacturing company. gbwa services multiple paper mills in the southeast united states.